Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    NMRC Provides Ebola Assays for W. Africa

    By Global Biodefense StaffOctober 22, 2014
    NMRC Researcher Creating Ebola Reagents
    After a large batch of Ebola specific PCR master mix is produced, the mix is aliquoted into individual tubes (NMRC)
    Share
    Facebook LinkedIn Reddit Email

    The Naval Medical Research Center (NMRC) has been supporting DoD’s interagency efforts since the early months of the Ebola outbreak, which began in December 2013, when initial cases were reported in Guinea and later spread to Sierra Leone and Liberia.

    A research team from NMRC’s Biological Defense Research Directorate (BDRD) has been busy producing more than 100,000 Ebola detection assays for the Medical Countermeasure System’s Critical Reagents Program (CRP), a part of the DoD Joint Project Management Office.

    “We were tasked to produce assays when the outbreak began and as the crisis continues to worsen, our production tempo has increased dramatically. Our team is producing these assays every day,” said Dr. Joan Gebhardt, head of Molecular Diagnostics at BDRD.

    Providing Important Biothreat Reagents

    As part of its mission, BDRD produces reagents and detection assays for research and development in the DoD, U.S. agencies and other partners. These Ebola-specific assays are used in West Africa. Blood samples are being collected from patients exhibiting symptoms and tested to detect infection. These assays are used to confirm patients with probable or suspected Ebola virus disease so they can be moved to treatment centers; the assays are also used for screening potential contacts of infected individuals.

    “This effort is a great example of what BDRD is capable of, quick rapid turnaround to provide detection assays for emerging infectious diseases anywhere on the globe,” said Cmdr. Guillermo Pimentel, Deputy Director of BDRD.

    According to the Centers for Disease Control and Prevention‘s (CDC) website the first Ebola virus species was discovered in 1976 in what is now the Democratic Republic of the Congo near the Ebola River.

    Since then, outbreaks have appeared sporadically. Ebola virus disease is characterized by fever, severe diarrhea, vomiting and can present as a severe viral hemorrhagic fever, an often fatal disease.

    The disease is often spread through families and friends because they come in close contact when caring for ill persons. The disease can also spread quickly within clinics or hospitals in resource poor settings with limited infection control capabilities.

    A Key Role in Protecting Military & Civilian Personnel

    BDRD is focused on research and development to protect U.S. military personnel and civilians from the threat of infectious diseases and biological attacks.

    The lab is certified as a National Laboratory within the CDC’s Laboratory Response Network for biological hazard testing and analysis. In addition, the production labs for molecular and immunological assays are under International Organization for Standardization ISO Guide 34/17025 accreditation.

    The research team supports Naval Sea Systems Command ensuring Fleet protection, outfitting the Navy and Marine Corps with bioweapons defense field testing capabilities and managing the proficiency testing program for the Joint Biological Agent and Identification and Detection System platform.

    Supporting the U.S. Government Health Security Agenda, the laboratory continues to expand their international research collaborations and programs.

    Article and image courtesy of Naval Medical Research Center Public Affairs, edited for context and format.

    Ebola
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleRapid, Portable Viral Diagnostic Available for Licensing
    Next Article Nanoscale Defenses for Biological and Chemical Threats

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Terrorism and the Pandemic: Weaponizing a Public Health Crisis

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy